Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.

Background: Warfarin has been widely used for the prevention and treatment of thromboembolism. Warfarin therapy depends on interaction between physiological, environmental, and genetic factors. Vitamin K epoxide reductase (VKORC1) and cytochrome P450 2C9 (CYP2C9) enzyme conjointly determine the warfarin maintenance dose.

Moraxella catarrhalis pneumonia in an AIDS patient: a case report.

Moraxella catarrhalis pneumonia, although in the immunocompromised patients is very uncommon for community-acquired pneumonia (CAP). It demonstrates a potential pathogen with high mortality when the presence of heavy numbers of organisms, intracellularly and extracellularly, in the sputum Gram's stained smears confirmed by cultures. In 2007, the authors reported a case of a 28-year-old Thai single male patient with acquired-immunodeficiency syndrome (AIDS) and Moraxella catarrhalis pneumonia who dramatically responded to two weeks of oral Amoxyclav (Amoxycillin trihydrate 500 milligrams + Clavulanic acid (Potassium clavulanate) 125 milligrams) treatment at 625 milligrams every 8 hours and then discharged.

Production of a monoclonal antibody against a yeast secreted antigen of Penicillium marneffei.

Monoclonal antibody against P. mameffei yeast secreted antigen was produced in order to develop a serological test for penicilliosis marneffei. The yeast form of P.

Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.

A randomized double blind placebo controlled trial to determine the efficacy and safety of combined-herbs (SH) given with zidovudine (ZDV) and zalcitabine (ddC) for the treatment of HIV infection in Thai adults was conducted in 3 hospitals in northern Thailand during 2002 to 2003. The eligible subjects were HIV-infected Thai adults who had never received anti-retrovirals, had a Karnofski Performance Score (KPS) of > or = 70, and had no opportunistic infections. The subjects were randomized to receive either a combination of ZDV 200 mg three times per day, ddC 0.